Why not ask Merck what the agreement will be with OncoSec if the combination of Keytruda and EP +IL-12 increases cancer overall response above Keytruda alone.
They'll say that UCSF has entered a clinical collaboration with Oncosec and Merck to evaluate Oncosec's EP+IL-12 with Merck's Anti PD-1. All 3 are in collaboration to share parts of the study through drugs, devices, clinical costs.